

Pharmacophore Mapping and Docking on Triazepane Derivatives as DPP-IV Inhibitors

Patil Swaraj^{1*}, Gurjar Sonam², Khodre Suraj³, Khodre Jyoti⁴, Patil Swadesh⁵

¹School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore-452017 MP, India,

²Government Higher secondary girls school, Sirali, MP, India,

³Government Ayurveda College, Rewa, Madhya Pradesh, India

⁴Home science girls college, Hosangabad, MP India,

⁵JNCT Bhopal, MP, India.

ABSTRACT

The molecule is inserted on the workspace of the Ligand scout 3.30b trial version. Energy was minimized by MMFF94 and pharmacophore part of compound is created which shows the hydrogen bonding, hydrophobic bonding and aromatic environment. Pharmacophore mapping shows hydrogen bond, hydrophobic bonding and aromatic hydrogen. The pdb (2OLE) of protein, ligand and reference (vildagliptin) is inserted on the workspace of the Molegro virtual docker 5.0 trial. Preparation of protein as well as ligand done, create surface area of protein, detection of cavity. The reference compound taken in docking is vildagliptin. The parameter selected in the docking studies were moldock optimizer, number of runs 10, population size 50, cross over rate 0.90 and max iteration 2000 and cavity selected is user define. Docking studies help in checking the interaction between protein and the ligand, interaction shows in docking are Glu 205, Arg 125, Gly 741, Trp 629, Ala 654, Asn 710, Asp 708, Val 711, His 740. The derivatives prepared by after docking and pharmacophore mapping helps in creating a most potent compound.

KEYWORDS: Pharmacophore, Vildagliptin, Moldock, Molegro virtual docker, Docking

*Corresponding Author:

Swaraj Patil

Project Assistant

DAVV School of Pharmacy,

Indore, Madhya Pradesh, India

Mobile No. +91-07415361595

E-mail: swarajpatil2006@gmail.com

INTRODUCTION

Due to type 2 diabetics several forms of neuropathy and peripheral neuropathy in diabetes has been known to approach 70%. DPP-4 preferentially cleaves incretin hormones, GLP-1 and GIP peptides with the amino acid alanine or proline in position 2 of the N-terminus of the peptide chain. Active GLP-1(7–36) amide was cut by DPP-4 to yield a dipeptide (His-Ala) and GLP-1(9–36)amide.¹⁻³ According to previous studies,⁴⁻⁷ effective glucose control, diverse antioxidants, and several neurotropic agents can help reduce diabetic polyneuropathy. Type 2 diabetes mellitus (T2DM) disease is characterized by several pathophysiologic defects including insulin resistance, excess hepatic glucose production and progressive pancreatic β cell dysfunction.⁸ It creates problem such as peripheral vascular insufficiencies, neuropathy and retinopathy end stage renal disease. Instead lifestyle interference, treatment of T2DM consists of oral antihyperglycaemic drugs and insulin.⁹ Suppress the various possible targets, the development of dipeptidyl peptidase IV inhibitors can prevent the degradation of the incretin hormones appears to be one of the most attractive, rational agents for the treatment of T2DM.¹⁰ Dipeptidyl peptidase IV also known as T-cell antigen CD26¹¹⁻¹² is present in group of class of serine protease family that selectively cleaves dipeptide from polypeptides, including proline or alanine at the N-terminal penultimate position.¹³⁻¹⁴

MATERIAL AND METHOD

Study data set of Triazepane derivatives (22 molecules) has been taken from the literature.¹⁵

Pharmacophore mapping

The molecule is inserted on the workspace of the Ligand scout 3.30b trial version. Energy was minimized by **MMFF94** and pharmacophore part of compound is created which shows the hydrogen bonding, hydrophobic bonding and aromatic environment. It was helpful in detection of the atom nature fig 1.

Docking studies

The pdb (2OLE) of protein, ligand and reference is inserted on the workspace of the Molegro virtual docker 5.0 trial. Preparation of protein as well as ligand, create surface area of protein, detection of cavity is done. The reference compound taken in docking is Vildagliptin. The parameter selected in the docking studies were moldock optimizer, number of runs 10, population size 50, cross over rate 0.90 and max iteration 2000 and cavity selected was user defined. The **hydrogen bond** interaction and hydrophobic bond interaction is shown in the fig 2. The receptor and ligand interaction is shown in the fig 3. The docking score of the compound is shown in the table 1.





































Fig 1: The nature of the atom is shown in A, B picture and color line shows the bonding.

Table 1: General structure of the compounds of cyanopyrrolidine derivatives and their biological activities (data set of 22 molecules)




S. No.	Compound	Ra	Rb	IC ₅₀ (nM)	log(1/IC ₅₀)
1	7	H	H	9800	5
2	13a	H		859	6.06
3	13b			578	6.23
4	13c			1200	5.92
5	13d	H		2500	5.6
6	13e	H		2900	5.53
7	13f	H		681	6.16
8	13g	H		609	6.21
9	13h			1800	5.74
10	13i			700	6.15

11	13j			401	6.39
12	13k			591	6.22
13	13l			151	6.82
14	13m	H		439	6.35
15	13n	H		216	6.66
16	13o			213	6.67
17	13p			98	7
18	17a	H	H	4500	5.34
19	17b		H	3300	5.48
20	17c			1600	5.79
21	17d			660	6.18
22	17e			853	6.06



A



B

Fig2. The Diagram A shows hydrogen bond interaction with His 740 and hydrophobic interaction with the receptor.




Fig 3: The Diagram A shows hydrogen bond interaction and B shows hydrophobic interaction with the receptor.

Table 2: The docking score of compound

Ligand	MolDock Score	Rerank Score	HBond
01	-67.7121	-34.8536	-2.399
02	27.058	494.955	0
03	50.3771	573.978	-0.338762
04	88.2865	1082.55	-0.524351
05	-73.4308	-43.7975	0.807523
06	-85.7064	7.265	-5.62086
07	-69.5396	-50.5174	-1.3724
08	-69.2886	-1.95484	0
09	-49.5066	55.8547	-0.798079
10	33.732	496.633	-0.986028
11	49.7545	584.274	0
12	-18.1281	567.026	-7.95629
13	-40.8473	500.308	0.149433
14	-48.8332	171.644	0.500079
15	-48.5538	156.765	-0.632443
16	-78.052	138.233	-3.70352
17	-55.9765	88.0899	-3.55236
18	-78.2862	28.664	-1.68366
19	-69.3886	-17.3276	-1.17221
20	-59.7999	-20.2719	-0.44184
21	-6.64839	702.189	-3.02646
22	-46.2925	-25.8067	3.55661
vildagliptin	-67.9615	33.8519	-3.69553

RESULT AND DISCUSSION

In pharmacophore modeling it is found out that C=O, F group shows the hydrogen bond acceptor nature while NH and NH₂ show the hydrogen bond donor nature. The hydrogen bonding of Arg 125 with Oxygen atom and His 740 with NH₂ is shown in the figure. The hydrophobic interaction between protein and ligand is found at Glu 205, Arg 125, Gly 741, Trp 629, Ala 654, Asn 710, Asp 708, Val 711, His 740. The derivatives prepared by after docking and pharmacophore mappin helps in creating a most potent compound. If in the compound steric interaction is more than compound is fitted in cavity accurately which is required for designing of structural based compound.

REFERENCE

1. Mentlein R. Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. *Regulatory Peptides*. 1999; 85: 9–24.
2. Gault VA, Parker JC, Harriott P et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP (3–42), is a GIP receptor antagonist in vivo. *The Journal of Endocrinology*. 2002; 175: 525–533.
3. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. *European Journal of Pharmacology*. 1996; 318: 429–435.
4. Boulton AJ, Malik RA, Arezzo JC et al. Diabetic somatic neuropathies. *Diabetes Care*. 2004; 27: 1458-1486.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998; 352: 837-853.
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998; 352: 854-865.
7. Argoff CE, Backonja MM, Belgrade MJ et al. Consensus guidelines: treatment planning and options. *Diabetic peripheral neuropathic pain, Mayo. Clin. Proc.* 2006; 81(4): S12-S25.
8. Bharatam PV, Patel DS, Adane L, Mittal A, Sundriyal S. Modeling and informatics in designing anti-diabetic agents, *Curr. Pharm. Des.* 2007; 13: 3518-30.
9. Geelhoed-Duijvestijn PH. Incretins: a new treatment option for type 2 diabetes. *Neth. J. Med.* 2007; 65: 60-64.
10. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. *Int. J. Clin. Pract.* 2006; 60: 1454- 70.

11. Haffner CD, McDougald DL, Reister SM, Thompson BD, Lenhard D, Johnson PR. 2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues potent inhibitors of DPP-IV. *Bioorg. Med. Chem. Lett.* 2005; 15: 5257- 5261.
12. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyloxy-1 naphthylamide. *Histochem.* 1966; 7: 197-201.
13. Abe M, Akiyama T, Umezawa Y, Yamamoto K, Yamajaki H, Nagai M, Muraoka Y. Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors. *Bioorg. Med. Chem.* 2005; 13: 785-797.
14. Heins J, Welker P, Schonlein C, Born I, Hartrodt B, Neubert K, Tsuru A. Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and prolinespecific endopeptidase from *Flavobacterium meningosepticum*, *Biochem. Biophys. Acta.* 1988; 954(2): 161-9.
15. Woul SP, Mi AJ, Mi SS, Sung WK et al. Synthesis and biological evaluation of triazepane derivatives as DPP-IV inhibitors. *Journal of Fluorine Chemistry.* 2009; 130: 1001–1010.